[go: up one dir, main page]

DE69308291D1 - Lactam Dipeptide mit HLE inhibierende Aktivität. - Google Patents

Lactam Dipeptide mit HLE inhibierende Aktivität.

Info

Publication number
DE69308291D1
DE69308291D1 DE69308291T DE69308291T DE69308291D1 DE 69308291 D1 DE69308291 D1 DE 69308291D1 DE 69308291 T DE69308291 T DE 69308291T DE 69308291 T DE69308291 T DE 69308291T DE 69308291 D1 DE69308291 D1 DE 69308291D1
Authority
DE
Germany
Prior art keywords
heterocyclic compounds
hle
dipeptides
lactam
inhibitory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69308291T
Other languages
English (en)
Other versions
DE69308291T2 (de
Inventor
Peter Berstein
Royston Martin Thomas
Peter Warner
Donald Wolanin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208379A external-priority patent/GB9208379D0/en
Priority claimed from GB929208380A external-priority patent/GB9208380D0/en
Priority claimed from GB929214448A external-priority patent/GB9214448D0/en
Priority claimed from GB929217362A external-priority patent/GB9217362D0/en
Priority claimed from GB929217364A external-priority patent/GB9217364D0/en
Priority claimed from GB929217363A external-priority patent/GB9217363D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DE69308291D1 publication Critical patent/DE69308291D1/de
Publication of DE69308291T2 publication Critical patent/DE69308291T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69308291T 1992-04-16 1993-04-15 Lactam Dipeptide mit HLE inhibierende Aktivität. Expired - Fee Related DE69308291T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB929208379A GB9208379D0 (en) 1992-04-16 1992-04-16 Heterocyclic amines
GB929208380A GB9208380D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds
GB929214448A GB9214448D0 (en) 1992-07-08 1992-07-08 Heterocyclic agents
GB929217362A GB9217362D0 (en) 1992-08-14 1992-08-14 Heterocyclic compounds
GB929217364A GB9217364D0 (en) 1992-08-14 1992-08-14 Heterocyclic agents
GB929217363A GB9217363D0 (en) 1992-08-14 1992-08-14 Heterocyclic amines
PCT/GB1993/000794 WO1993021212A1 (en) 1992-04-16 1993-04-15 Lactam dipeptides having hle inhibiting activity

Publications (2)

Publication Number Publication Date
DE69308291D1 true DE69308291D1 (de) 1997-04-03
DE69308291T2 DE69308291T2 (de) 1997-06-26

Family

ID=27547161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69308291T Expired - Fee Related DE69308291T2 (de) 1992-04-16 1993-04-15 Lactam Dipeptide mit HLE inhibierende Aktivität.

Country Status (13)

Country Link
EP (1) EP0630382B1 (de)
JP (1) JPH07505873A (de)
AT (1) ATE149175T1 (de)
AU (1) AU4076993A (de)
CA (1) CA2132543A1 (de)
DE (1) DE69308291T2 (de)
FI (1) FI944802L (de)
GB (1) GB9307555D0 (de)
HU (1) HUT70430A (de)
IL (1) IL105424A0 (de)
MX (1) MX9302215A (de)
NO (1) NO943909D0 (de)
WO (1) WO1993021212A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015791A (en) * 1994-11-21 2000-01-18 Cortech Inc. Serine protease inhibitors-cycloheptane derivatives
US6001814A (en) * 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors
US6100238A (en) * 1994-11-21 2000-08-08 Cortech Inc. Indole and tetrahydroisoquinoline containing Alpha-keto oxadiazoles as serine protease inhibitors
US6001813A (en) * 1994-11-21 1999-12-14 Cortech Inc. Val-pro containing α-keto oxadiazoles as serine protease inhibitors
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US6150334A (en) * 1994-11-21 2000-11-21 Cortech, Inc. Serine protease inhibitors-tripeptoid analogs
US5998379A (en) * 1994-11-21 1999-12-07 Cortech Inc. Serine protease inhibitors-proline analogs
US6001811A (en) * 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors--N-substituted derivatives
US6159938A (en) * 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
US20020119985A1 (en) 1994-11-21 2002-08-29 Albert Gyorkos Serine protease inhibitors
DE69634122D1 (de) * 1995-04-27 2005-02-03 Mitsubishi Pharma Corp Heterocyclische amidverbindungen und deren medizinische verwendung
CN1247542A (zh) * 1996-12-06 2000-03-15 康泰驰公司 丝氨酸蛋白酶抑制剂
US6656910B2 (en) 1997-12-04 2003-12-02 Cortech, Inc. Serine protease inhibitors
AU4330899A (en) 1998-06-03 2000-06-19 Cortech, Inc. Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
EP1437381A4 (de) 2001-07-30 2006-08-30 Sanko Chemical Industry Co Ltd Antistatikzusammensetzung und herstellungsverfahren dafür
IL163453A0 (en) 2004-08-10 2009-02-11 Yeda Res & Dev Enzyme inhibitor in leukemia
SG10201401836RA (en) * 2009-04-27 2014-10-30 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
CN114650819A (zh) 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369391A3 (de) * 1988-11-15 1991-09-25 Boehringer Ingelheim Pharmaceuticals Inc. N-substituierte Amide
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides

Also Published As

Publication number Publication date
CA2132543A1 (en) 1993-10-28
FI944802A7 (fi) 1994-10-12
ATE149175T1 (de) 1997-03-15
HUT70430A (en) 1995-10-30
HU9402968D0 (en) 1995-02-28
NO943909L (no) 1994-10-14
IL105424A0 (en) 1993-08-18
AU4076993A (en) 1993-11-18
MX9302215A (es) 1993-10-01
FI944802A0 (fi) 1994-10-12
GB9307555D0 (en) 1993-06-02
EP0630382B1 (de) 1997-02-26
NO943909D0 (no) 1994-10-14
DE69308291T2 (de) 1997-06-26
FI944802L (fi) 1994-10-12
WO1993021212A1 (en) 1993-10-28
JPH07505873A (ja) 1995-06-29
EP0630382A1 (de) 1994-12-28

Similar Documents

Publication Publication Date Title
NO943910D0 (no) Laktam-peptider med HLE-hemmende virkning
TW262475B (en) Heterocyclic amides, intermediates and process for their preparation and pharmaceutical compositions containing them
NO923197D0 (no) Substituerte heterocykliske forbindelser
EP0636143A1 (de) Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer.
DE69308291D1 (de) Lactam Dipeptide mit HLE inhibierende Aktivität.
FI946202A0 (fi) Fluoria sisältäviä dipeptidejä inhibiittoreina ihmisen lenkosyyttielastaasi-inhibiittoreita vastaan
ATE157099T1 (de) Laktam-dipeptide mit inhibierender wirkung auf die menschliche leukozytenelastase
DK0397427T3 (da) Fluoramidderivater med human leukocytelastase-inhiberende aktivitet
ES2055866T3 (es) Derivados trifluorcetopeptidos utiles como inhibidores de elastasa de leucocitos humanos.
NO944659L (no) Laktam-dipeptider med HLE-inhiberende aktivitet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee